EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2981	(("0000560") or ("0000126")).PN. or ((546/342) or (544/297) or (514/275) or (544/382) or (514/252.12)).CCLS.	US-PGPUB; USPAT	OR	OFF	2006/08/21 17:49
L2	1744	1 and chemical and compound	US-PGPUB; USPAT	OR	ON	2006/08/21 18:04
L3	0	1 and chemical and compound and hPPAR	US-PGPUB; USPAT	OR	ON	2006/08/21 18:04

C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\utd.str



chain nodes :
1 2 3 4 5 6 7 8 13 22 23 24 25 26 27 33 34 35 43 45
ring nodes :
16 17 18 19 20 21 36 37 38 39 40 41
chain bonds :
1-2 2-3 2-4 4-13 6-7 13-18 21-33 22-23 25-26 33-34 34-35 34-43
ring bonds :
16-17 16-21 17-18 18-19 19-20 20-21 36-37 36-41 37-38 38-39 39-40 40-41
exact/norm bonds :
4-13 13-18 21-33 25-26 33-34 34-35 34-43
exact bonds :
2-4 6-7 22-23
normalized bonds :
1-2 2-3 16-17 16-21 17-18 18-19 19-20 20-21 36-37 36-41 37-38 38-39 39-40 40-41
isolated ring systems :
containing 16 : 36 :

G1:[*1],[*2],[*3]

G2:[*4],[*5],[*6],[*7],[*8]

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 13:CLASS 16:Atom 17:Atom
18:Atom

19:Atom 20:Atom 21:Atom 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 33:CLASS
34:CLASS 35:CLASS 36:Atom 37:Atom 38:Atom 39:Atom 40:Atom 41:Atom 43:CLASS 45:CLASS 47:Atom

10518778

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1612bxr

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 4	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 5	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 6	MAY 11	KOREAPAT updates resume
NEWS 7	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 8	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 9	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 10	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS 11	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS 12	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 13	JUl 11	CHEMSAFE reloaded and enhanced
NEWS 14	JUl 14	FSTA enhanced with Japanese patents
NEWS 15	JUl 19	Coverage of Research Disclosure reinstated in DWPI
NEWS 16	AUG 09	INSPEC enhanced with 1898-1968 archive

NEWS EXPRESS	JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:44:31 ON 21 AUG 2006

=> file reg

Updated Search

10518778

COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 0.42 | 0.42

FILE 'REGISTRY' ENTERED AT 13:45:23 ON 21 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 AUG 2006 HIGHEST RN 902860-89-3
DICTIONARY FILE UPDATES: 20 AUG 2006 HIGHEST RN 902860-89-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
=>
Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\utd.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 14:03:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 37467 TO ITERATE

5.3% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 737776 TO 760904
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

Updated Search

10518778

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 14:03:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 746924 TO ITERATE

99.2% PROCESSED 741084 ITERATIONS 197 ANSWERS

100.0% PROCESSED 746924 ITERATIONS 197 ANSWERS
SEARCH TIME: 00.00.17

L3 197 SEA SSS FUL L1

=>

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	180.14	180.56

FILE 'HCAPLUS' ENTERED AT 14:03:46 ON 21 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 21 Aug 2006 VOL 145 ISS 9
FILE LAST UPDATED: 20 Aug 2006 (20060820/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3
L4 26 L3

=> s l4 and beswick, p?/au
57 BESWICK, P?/AU
L5 1 L4 AND BESWICK, P?/AU

=> d l5, ibib abs hitstr, 1

L5 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:2818 HCAPLUS
DOCUMENT NUMBER: 140:59406
TITLE: Preparation of [[[(hetero)arylamino]methyl]phenoxy]ace
tic acid derivatives as hPPAR activators for treatment
of cardiovascular disease and related disorders

Updated Search

10518778

INVENTOR(S): Beswick, Paul John; Harling, John David; Kleanthous, Savvas; Patel, Vipulkumar Kantibhai; Simpson, Juliet
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000762	A2	20031231	WO 2003-EP6416	20030618
WO 2004000762	A3	20041014		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2489359	AA	20031231	CA 2003-2489359	20030618
AU 2003245963	A1	20040106	AU 2003-245963	20030618
EP 1513795	A2	20050316	EP 2003-738057	20030618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011935	A	20050322	BR 2003-11935	20030618
CN 1675168	A	20050928	CN 2003-819322	20030618
JP 2005534673	T2	20051117	JP 2004-514762	20030618
NO 2004005327	A	20050310	NO 2004-5327	20041203
US 2006074111	A1	20060406	US 2004-518778	20041217
PRIORITY APPLN. INFO.:			GB 2002-14254 A	20020620
			WO 2003-EP6416 W	20030618

OTHER SOURCE(S): MARPAT 140:59406
GI

Updated Search



I



II

AB Title compds. I [wherein R1 and R2 = independently H or alkyl; X = a bond, CH2, or O; R3 and R4 = independently H, alkyl, OCH3, CF3, allyl, or halo; X1 = CH2, SO2, or CO; R5 = alkenyl, alkanoyl, alkylsulfonyl, or (un)substituted alkyl(phenyl); R6 = (un)substituted Ph or 6-membered heteroaryl; or pharmaceutically acceptable salts, solvates, or hydrolyzable esters thereof] were prepared as human peroxisome proliferator activated receptor (hPPAR) activators. For example, coupling of Et 2-methyl-2-[2-methyl-4-[[[4-(trifluoromethyl)benzyl]amino]methyl]phenoxy]propanoate with 2-bromo-6-[4-(trifluoromethyl)phenyl]pyridine in the presence of Pd(OAc)2, (R)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, and cesium carbonate in toluene gave the tertiary amine. Saponification with NaOH in THF provided the acid II. Compds. of the invention showed at least 50% activation of hPPARδ relative to the pos. control at concns. of 10-7 M or less. Thus, I and their pharmaceutical compns. are useful for the treatment of hPPAR mediated conditions, such as dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia, or anorexia nervosa (no data).

IT 637353-35-6P, [4-[[Butyl[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-36-7P, [4-[[(2-Methoxyethyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-37-8P, [2-Methyl-4-[[(pentyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]phenoxy]acetic acid 637353-38-9P, [4-[[(2-Cyclopropylethyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-39-0P, [2-Methyl-4-[[propyl[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]phenoxy]acetic acid 637353-40-3P, [2-Methyl-4-[[[2-(methylthio)ethyl][4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]phenoxy]acetic acid 637353-41-4P, [4-[[Butyl[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-42-5P, [4-[[(2-Methoxyethyl)[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-43-6P, [4-[[(Butyryl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-44-7P, [2-Methyl-4-

[[(propylsulfonyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]phenoxy]acetic acid 637353-45-8P, [4-[[Butyl[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]sulfonyl]-2-methylphenoxy]acetic acid 637353-46-9P, [2-Methyl-4-[[(pentyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]sulfonyl]phenoxy]acetic acid 637353-47-0P, [4-[[(2-Cyclopropylethyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]sulfonyl]-2-methylphenoxy]acetic acid 637353-56-1P, [4-[[Butyl(2,4'-dimethyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy]acetic acid 637353-57-2P, [4-[[Butyl(4'-fluoro-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy]acetic acid 637353-58-3P, [4-[[Butyl(4'-cyano-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy]acetic acid 637353-59-4P, [4-[[Butyl(4'-methoxy-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy]acetic acid 637353-60-7P, [4-[[Butyl(4'-chloro-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy]acetic acid 637353-61-8P, [4-[[(4'-Chloro-2-methyl-1,1'-biphenyl-3-yl)(2-methoxyethyl)amino]methyl]-2-methylphenoxy]acetic acid 637353-62-9P, [4-[[(2,4'-Dimethyl-1,1'-biphenyl-3-yl)(2-methoxyethyl)amino]methyl]-2-methylphenoxy]acetic acid 637353-63-0P, [4-[[(2-Methoxyethyl)(4'-methoxy-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy]acetic acid 637353-64-1P, [2-Methyl-4-[[[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl](propyl)amino]methyl]phenoxy]acetic acid 637353-65-2P, [4-[[(4'-Chloro-2-methyl-1,1'-biphenyl-3-yl)(propyl)amino]methyl]-2-methylphenoxy]acetic acid 637353-66-3P, [4-[[(2,4'-Dimethyl-1,1'-biphenyl-3-yl)(propyl)amino]methyl]-2-methylphenoxy]acetic acid 637353-67-4P, [4-[[(4'-Fluoro-2-methyl-1,1'-biphenyl-3-yl)(propyl)amino]methyl]-2-methylphenoxy]acetic acid 637353-68-5P, [4-[[(4'-Cyano-2-methyl-1,1'-biphenyl-3-yl)(propyl)amino]methyl]-2-methylphenoxy]acetic acid 637353-69-6P, [4-[[(4'-Methoxy-2-methyl-1,1'-biphenyl-3-yl)(propyl)amino]methyl]-2-methylphenoxy]acetic acid 637353-84-5P, [4-[[Butyl[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]sulfonyl]-2-methylphenoxy]acetic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(hPPAR activator; preparation of [[[(hetero)arylamino]methyl]phenoxy]acetic acid derivs. as hPPAR activators for treatment of cardiovascular disease and related disorders)

RN 637353-35-6 HCAPLUS

CN Acetic acid, [4-[[butyl[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-36-7 HCAPLUS

CN Acetic acid, [4-[[(2-methoxyethyl)[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search





RN 637353-37-8 HCAPLUS
CN Acetic acid, [2-methyl-4-[[pentyl[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-38-9 HCAPLUS
CN Acetic acid, [4-[[(2-cyclopropylethyl)[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-39-0 HCAPLUS
CN Acetic acid, [2-methyl-4-[[propyl[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 637353-40-3 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-(methylthio)ethyl][4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)





RN 637353-41-4 HCAPLUS
CN Acetic acid, [4-[[butyl[2-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-42-5 HCAPLUS
CN Acetic acid, [4-[[(2-methoxyethyl)[2-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search





RN 637353-43-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(1-oxobutyl)[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-44-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(propylsulfonyl)[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-45-8 HCAPLUS
CN Acetic acid, [4-[[butyl[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]sulfonyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-46-9 HCAPLUS

Updated Search

10518778

CN Acetic acid, [2-methyl-4-[[pentyl[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]sulfonyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-47-0 HCAPLUS
CN Acetic acid, [4-[[(2-cyclopropylethyl)[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]sulfonyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-56-1 HCAPLUS
CN Acetic acid, [4-[[butyl(2,4'-dimethyl[1,1'-biphenyl]-3-yl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-57-2 HCAPLUS
CN Acetic acid, [4-[[butyl(4'-fluoro-2-methyl[1,1'-biphenyl]-3-yl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 637353-58-3 HCAPLUS
CN Acetic acid, [4-[[butyl(4'-cyano-2-methyl[1,1'-biphenyl]-3-yl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-59-4 HCAPLUS
CN Acetic acid, [4-[[butyl(4'-methoxy-2-methyl[1,1'-biphenyl]-3-yl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-60-7 HCAPLUS
CN Acetic acid, [4-[[butyl(4'-chloro-2-methyl[1,1'-biphenyl]-3-yl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-61-8 HCAPLUS
CN Acetic acid, [4-[[(4'-chloro-2-methyl[1,1'-biphenyl]-3-yl)(2-methoxyethyl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search





RN 637353-62-9 HCAPLUS
CN Acetic acid, [4-[[(2,4'-dimethyl[1,1'-biphenyl]-3-yl)(2-methoxyethyl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)





RN 637353-63-0 HCAPLUS
CN Acetic acid, [4-[[(2-methoxyethyl)(4'-methoxy-2-methyl[1,1'-biphenyl]-3-yl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)





RN 637353-64-1 HCAPLUS

Updated Search

CN Acetic acid, [2-methyl-4-[[[2-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]propylamino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-65-2 HCAPLUS
CN Acetic acid, [4-[[(4'-chloro-2-methyl[1,1'-biphenyl]-3-yl)propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-66-3 HCAPLUS
CN Acetic acid, [4-[[(2,4'-dimethyl[1,1'-biphenyl]-3-yl)propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-67-4 HCAPLUS
CN Acetic acid, [4-[[(4'-fluoro-2-methyl[1,1'-biphenyl]-3-yl)propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-68-5 HCAPLUS
CN Acetic acid, [4-[[(4'-cyano-2-methyl[1,1'-biphenyl]-3-yl)propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search

10518778



RN 637353-69-6 HCAPLUS
CN Acetic acid, [4-[[(4'-methoxy-2-methyl[1,1'-biphenyl]-3-yl)propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-84-5 HCAPLUS
CN Acetic acid, [4-[[butyl[2-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]sulfonyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 13:44:31 ON 21 AUG 2006)

FILE 'REGISTRY' ENTERED AT 13:45:23 ON 21 AUG 2006
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 197 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 14:03:46 ON 21 AUG 2006
L4 26 S L3
L5 1 S L4 AND BESWICK, P?/AU

=> s l4 not l5
L6 25 L4 NOT L5

=> s l6 and harling, j?/au
66 HARLING, J?/AU
L7 0 L6 AND HARLING, J?/AU

Updated Search

10518778

```
=> s l6 and kleanthous, s?/au
            11 KLEANTHOUS, S?/AU
L8           0 L6 AND KLEANTHOUS, S?/AU

=> s l6 and lambert, m?/au
           961 LAMBERT, M?/AU
L9           0 L6 AND LAMBERT, M?/AU

=> s l6 and kantibhai, v?/au
             0 KANTIBHAI, V?/AU
L10          0 L6 AND KANTIBHAI, V?/AU

=> s l6 and simpson, j?/au
          2346 SIMPSON, J?/AU
L11          0 L6 AND SIMPSON, J?/AU

=> d his

     (FILE 'HOME' ENTERED AT 13:44:31 ON 21 AUG 2006)

     FILE 'REGISTRY' ENTERED AT 13:45:23 ON 21 AUG 2006
L1              STRUCTURE UPLOADED
L2            0 S L1
L3          197 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 14:03:46 ON 21 AUG 2006
L4           26 S L3
L5            1 S L4 AND BESWICK, P?/AU
L6           25 S L4 NOT L5
L7            0 S L6 AND HARLING, J?/AU
L8            0 S L6 AND KLEANTHOUS, S?/AU
L9            0 S L6 AND LAMBERT, M?/AU
L10           0 S L6 AND KANTIBHAI, V?/AU
L11           0 S L6 AND SIMPSON, J?/AU

=> d l4, ibib abs hitstr, 1-25

L4   ANSWER 1 OF 26  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2006:655920  HCAPLUS
DOCUMENT NUMBER:          145:124613
TITLE:                    Preparation of carboxylic acid derivatives having
                          three cyclic moieties as anticoagulants
INVENTOR(S):              Ishihara, Tsukasa; Miura, Masanori; Ohne, Kazuhiko;
                          Takuwa, Tomofumi; Shirakami, Shohei; Ibuka, Ryotaro;
                          Ohnuki, Kei; Seki, Norio; Shigenaga, Takeshi;
                          Hirayama, Fukushi; Hirabayashi, Akihito; Kai,
                          Yuichiro; Kobayashi, Junichi; Hirasawa, Hideaki;
                          Kondou, Atsushi; Yamada, Ken
PATENT ASSIGNEE(S):       Astellas Pharma Inc., Japan
SOURCE:                   PCT Int. Appl., 198 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
```

Updated Search

10518778

WO 2006070878 A1 20060706 WO 2005-JP24096 20051228

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2004-380131 A 20041228

GI



I

AB The title compds. [I; ring A = aryl or heteroaryl ring; ring B = benzene, naphthalene, or monocyclic or bicyclic heteroaryl ring; ring C = cycloalkyl, aryl, or heterocyclic ring; m, n, p = an integer of 0-3; R1 = NH2, CH2NH2, CONH2, C(:NH)NH2, C(:NOH)NH2, C(:NH)NH-CO2-(optionally substituted lower alkyl), 5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl; R2, R3 = lower alkyl, halo-lower alkyl, halo, oxo, cyano, NO2, halo-lower alkoxy, NR0R00, SR0, S(O)R0, SO2R0, SO2NR0R00, NR0SO2R00, COR0, CO2R0, CONR0R00, NR0COR00, NR0CO-(halo-lower alkyl), cycloalkyl, aryl, heterocyclyl, etc.; R0, R00 = H, lower alkyl; R4 = lower alkyl, lower alkenyl, cycloalkyl, aryl, heterocyclyl, halo, oxo, cyano, NO2, OR6, NR6R6a, SR6, SOR6, SO2R6, SO2NR6R6a, NR6SO2R6a, NR6SO2NR6R6a, NR6SO2NR6aCO2R6a, COR6, CO2R6, CONR6R6a, cycloalkyl, aryl, heterocyclyl, etc.; R6, R6a = H, each (un)substituted lower alkyl, lower alkenyl, cycloalkyl, aryl, or heterocyclyl; R5 = OR0, NR0R00, N(R0)-lower alkylene-OR00; J = NR0CO, CONR0, NR0CONR0, NR0-lower alkylene, lower alkylene-NR0CO; L = NR0-lower alkylene, NR0-lower alkenylene, lower alkylene, lower alkenylene; X = a single bond, (un)substituted NH, S, CO, SO, SO2, lower alkylene-O, lower alkylene-(un)substituted NH; Y = a single bond, each (un)substituted lower alkylene or lower alkenylene] or pharmaceutically acceptable salt thereof are prepared These compds. such as phenoxyacetic acid and phenylpropanoic acid derivs. or salts thereof have an anticoagulant effect based on the inhibition of the activated blood coagulation factor VII and, therefore, are useful as blood coagulation inhibitors or preventives/remedies for diseases caused by thrombus or embolus. They are also selective inhibitors of activated blood coagulation factor VII over activated blood coagulation factor X and thrombin. The above diseases include ischemic heart diseases, restenosis after angioplasty, cerebral thrombosis, transient cerebral ischemia, peripheral arterial obstruction, Charcot's syndrome (intermittent claudication), deep venous thrombosis, pulmonary embolism, disseminated intravascular coagulation (DIC), thrombogenesis

Updated Search

after heart valve replacement surgery, coagulation or inflammation of circulating blood during external blood circulation, arteriosclerosis, and cancer. For example, [(3-([[(2-([[(2-amino-1H-benzimidazol-5-yl)amino]carbonyl)-4-chlorophenyl)amino]methyl)biphenyl-2-yl)oxy]acetic acid in vitro inhibited activated blood coagulation factor VII over activated blood coagulation factor X and thrombin with IC50 of 0.36, ≥100, and ≥100 μM, resp.

IT 897632-55-2P, [2-[[[2-[[[4-[Amino(imino)methyl]phenyl]amino]carbonyl]-4-chlorophenyl]amino]methyl]-4-[(dimethylamino)methyl]-6-ethoxyphenoxy]acetic acid hydrochloride 897635-46-0P 897635-49-3P 897636-55-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carboxylic acid derivs. having three cyclic moieties as activated blood coagulation factor VII inhibitors and anticoagulants)

RN 897632-55-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



●x HCl

RN 897635-46-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 897635-45-9
CMF C30 H36 Cl N5 O5



Updated Search

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 897635-49-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



●x HCl

RN 897636-55-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 897636-54-3
CMF C29 H34 Cl N5 O5



CM 2

Updated Search

CRN 64-18-6
CMF C H2 O2

O═CH—OH

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:117042 HCAPLUS
DOCUMENT NUMBER: 144:212778
TITLE: Preparation of pyrazole derivatives and other heterocyclic compounds as peroxisome proliferator-activated receptor α and γ agonists
INVENTOR(S): Kagechika, Katsuji; Yamaguchi, Mitsuhiro; Shibata, Yoshihiro; Usui, Hiroyuki
PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 186 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006013939	A1	20060209	WO 2005-JP14332	20050804

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2004-229445 A 20040805
OTHER SOURCE(S): MARPAT 144:212778
GI



I

AB The title compds. I [ring A = 5-member aromatic heterocyclic ring; X, Y, Z =

N, C; m = 0 - 3; n = 1 - 5; Q = (un)substituted benzene ring; R1 = (un)substituted Ph, naphthyl, 5- or 6-member aromatic ring; R2 = (un)substituted alkyl, (un)substituted carbamoyl, (un)substituted Ph, etc.; R3, R4 = H, alkyl; R5 = H, alkyl, (un)substituted benzyl; R6 = H, OH, halo, etc.; when m = ≥ 2, the R6 substituents may be the same or different] are prepared Thus, 2-[4-[[[1-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-ylmethyl]furan-2-ylmethylamino]methyl]phenoxy]-2-methylpropionic acid was prepared in 2 steps from 4-chloromethyl-1-(4-chlorophenyl)-3-methyl-1H-pyrazole and 2-[4-[[(furan-2-ylmethyl)amino]methyl]phenoxy]-2-methylpropionic acid Et ester. In GAL4-hPPAR transactivation assays (PPAR α), compds. of this invention showed EC50 values of 0.0028 μM to 0.08 μM.

IT 875656-84-1P 875656-86-3P 875656-87-4P
875656-96-5P 875656-98-7P 875657-01-5P
875657-02-6P 875657-03-7P 875657-04-8P
875657-05-9P 875657-06-0P 875657-07-1P
875657-08-2P 875657-09-3P 875657-10-6P
875657-11-7P 875657-12-8P 875657-13-9P
875657-14-0P 875657-15-1P 875657-16-2P
875657-17-3P 875657-18-4P 875657-19-5P
875657-20-8P 875657-21-9P 875657-22-0P
875657-23-1P 875657-24-2P 875657-25-3P
875657-26-4P 875657-27-5P 875657-28-6P
875657-29-7P 875657-30-0P 875657-31-1P
875657-32-2P 875657-33-3P 875657-34-4P
875657-35-5P 875657-36-6P 875657-37-7P
875657-38-8P 875657-39-9P 875657-40-2P
875657-41-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole derivs. and other heterocyclic compds. as peroxisome proliferator-activated receptor α and γ agonists)

RN 875656-84-1 HCAPLUS

CN Propanoic acid, 2-[4-[[(2-furanylmethyl)[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875656-86-3 HCAPLUS

Updated Search

CN Propanoic acid, 2-[4-[[(2-furanylmethyl)[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875656-87-4 HCAPLUS

CN Propanoic acid, 2-[4-[[(2-furanylmethyl)[2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)ethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875656-96-5 HCAPLUS

CN Propanoic acid, 2-[4-[[(2-amino-2-oxoethyl)[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search



RN 875656-98-7 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(methylamino)-2-oxoethyl][(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-01-5 HCAPLUS
CN Propanoic acid, 2-[4-[[[2-(dimethylamino)-2-oxoethyl][(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-02-6 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-1,3,4-oxadiazol-2-yl)methyl][(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search



RN 875657-03-7 HCAPLUS
CN Propanoic acid, 2-[4-[[(3-methoxypropyl)[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-04-8 HCAPLUS
CN Propanoic acid, 2-[4-[[(2-methoxyethyl)[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)





RN 875657-05-9 HCAPLUS

Updated Search

CN Propanoic acid, 2-[4-[[(2-methoxyethyl)[[5-methyl-2-(4-methylphenyl)-2H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)





RN 875657-06-0 HCAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(methylamino)-2-oxoethyl][[5-methyl-2-(4-methylphenyl)-2H-1,2,3-triazol-4-yl]methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-07-1 HCAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[[[[5-methyl-2-(4-methylphenyl)-2H-1,2,3-triazol-4-yl]methyl][(5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-08-2 HCAPLUS
CN Propanoic acid, 2-[4-[[(3-methoxypropyl)[[5-methyl-2-(4-methylphenyl)-2H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-09-3 HCAPLUS
CN Propanoic acid, 2-[4-[[(3-methoxypropyl)[[5-methyl-2-(4-methylphenyl)-2H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 875657-10-6 HCAPLUS
CN Propanoic acid, 2-[4-[[(2-methoxyethyl)[[5-methyl-2-(3-methylphenyl)-2H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-

Updated Search

10518778

(9CI) (CA INDEX NAME)





RN 875657-11-7 HCAPLUS
CN Propanoic acid, 2-[4-[[(2-methoxyethyl)[[5-methyl-2-(3-methylphenyl)-2H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 875657-12-8 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(methylamino)-2-oxoethyl][[5-methyl-2-(3-methylphenyl)-2H-1,2,3-triazol-4-yl]methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search



RN 875657-13-9 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[[5-methyl-2-(3-methylphenyl)-2H-1,2,3-triazol-4-yl]methyl][(5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-14-0 HCAPLUS
CN Propanoic acid, 2-[4-[[(3-methoxypropyl)[[5-methyl-2-(3-methylphenyl)-2H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-15-1 HCAPLUS
CN Propanoic acid, 2-[4-[[(3-methoxypropyl)[[5-methyl-2-(3-methylphenyl)-2H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Updated Search



● HCl

RN 875657-16-2 HCAPLUS
CN Propanoic acid, 2-[4-[[[[2-(4-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl][2-(methylamino)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-17-3 HCAPLUS
CN Propanoic acid, 2-[4-[[[[2-(4-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl][(5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-18-4 HCAPLUS
CN Propanoic acid, 2-[4-[[[[2-(3-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl][2-(methylamino)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-

methyl- (9CI) (CA INDEX NAME)



RN 875657-19-5 HCAPLUS
CN Propanoic acid, 2-[4-[[[2-(3-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl][(5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-20-8 HCAPLUS
CN Propanoic acid, 2-[4-[[[2-(4-methoxyphenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl][(5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-21-9 HCAPLUS
CN Propanoic acid, 2-[4-[[[[2-(4-methoxyphenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl][2-(methylamino)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-22-0 HCAPLUS
CN Propanoic acid, 2-[4-[[[[2-(3,4-dimethylphenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl][2-(methylamino)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-23-1 HCAPLUS
CN Propanoic acid, 2-[4-[[[[2-[4-(2-methoxyethoxy)phenyl]-5-methyl-2H-1,2,3-triazol-4-yl]methyl][2-(methylamino)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search



RN 875657-24-2 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(methylamino)-2-oxoethyl][2-(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)ethyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-25-3 HCAPLUS
CN Propanoic acid, 2-[4-[[(2-amino-2-oxoethyl)[2-(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)ethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-26-4 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-1,3,4-oxadiazol-2-yl)methyl][2-(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)ethyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search



RN 875657-27-5 HCAPLUS
CN Propanoic acid, 2-[4-[[(2-methoxyethyl)[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-28-6 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl](3,3,3-trifluoropropyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-29-7 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl](3,3,3-trifluoropropyl)amino]methyl]phenoxy]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 875657-30-0 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(methylamino)-2-oxoethyl][(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search



RN 875657-31-1 HCAPLUS
CN Propanoic acid, 2-[4-[[[2-(dimethylamino)-2-oxoethyl][(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-32-2 HCAPLUS
CN Propanoic acid, 2-[4-[[(5-isoxazolylmethyl)[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search



RN 875657-33-3 HCAPLUS
CN Propanoic acid, 2-[4-[[[[1-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]methyl][2-(methylamino)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



Updated Search



RN 875657-34-4 HCAPLUS
CN Propanoic acid, 2-[4-[[[[2-(3,4-dimethylphenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl][(5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-35-5 HCAPLUS
CN Propanoic acid, 2-[4-[[[[2-(4-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl](2-methoxyethyl)amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-36-6 HCAPLUS
CN Propanoic acid, 2-[4-[[(2-methoxyethyl)[[2-(4-methoxyphenyl)-5-methyl-2H-

Updated Search

1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)





RN 875657-37-7 HCAPLUS
CN Propanoic acid, 2-[4-[[(2-hydroxyethyl)[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-38-8 HCAPLUS
CN Propanoic acid, 2-[4-[[(2-methoxyethyl)[[1-(4-methylphenyl)-1H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)





RN 875657-39-9 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-1,3,4-oxadiazol-2-yl)methyl][[1-(4-methylphenyl)-1H-1,2,3-triazol-4-yl]methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-40-2 HCAPLUS
CN Propanoic acid, 2-[4-[[(2,2-difluoroethyl)[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search



RN 875657-41-3 HCAPLUS
CN Propanoic acid, 2-[4-[[(2,2-difluoroethyl)[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, hydrochloride (5:3) (9CI) (CA INDEX NAME)



●3/5 HCl

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:75092 HCAPLUS
DOCUMENT NUMBER: 144:170792
TITLE: Preparation of trisubstituted nitrogen modulators, particularly N,N-dibenzylarylsulfonamide inhibitors, of tyrosine phosphatases for treating metabolic disorders, autoimmune diseases and neoplasm
INVENTOR(S): Semple, Joseph E.; Rideout, Darryl; Nutt, Ruth F.; Shernderovich, Mark; Wang, Jing; Mylvaganam, Shankari; Wu, Feiyue; Tsai, Chung-Ying; Yalamoori, Venkatachalapathi; Loweth, Colin J.
PATENT ASSIGNEE(S): Cengent Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 238 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006009876	A2	20060126	WO 2005-US21540	20050617
WO 2006009876	A3	20060330		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

Updated Search

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006135773 A1 20060622 US 2005-156230 20050617

PRIORITY APPLN. INFO.: US 2004-581251P P 20040617
US 2004-634200P P 20041207
US 2004-638419P P 20041222

OTHER SOURCE(S): MARPAT 144:170792

GI



I



II

AB The invention is related to the preparation of trisubstituted nitrogen compds. I [L1-L3 = independently N-C single bond (G1, G2, or G3 are directly bonded to N by a single bond), alkylene, sulfonyl, amido, etc.; G1-G3 = alkyl, aryl, cyanobiaryl, etc., optionally substituted with carboxy, phosphonato, phosphonatoalkyl, phosphonatohaloalkyl, amido, etc.], and their pharmaceutically acceptable derivs., including N,N-dibenzylarylsulfonamides. The invention is also related to the use of compds. I, and their compns., for modulating the activity of protein tyrosine phosphatases, especially PTP-1B. Thus, reacting (bromodifluoromethyl)phosphonic acid di-Et ester with bis(4-iodobenzyl)carbamic acid tert-Bu ester (preparation given), followed by reaction with 2-chlorobenzenesulfonyl chloride and ester hydrolysis gave phosphonic acid II. In a pNPP assay, selected I displayed IC50 values of less than 99 nM for the inhibition of PTP-1B. I are useful for treating metabolic disorders, autoimmune diseases and neoplasm.

Updated Search

10518778

IT 874567-71-2P, 2-Carboxymethoxy-5-[[(4-methylsulfonylbenzyl)(2-methoxyphenylsulfonyl)amino]methyl]benzoic acid 874568-56-6P, 5-[[[(Biphenyl-2-yl)methyl](2-methoxyphenylsulfonyl)amino]methyl]-2-(carboxymethoxy)benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of N,N-dibenzylarylsulfonamide inhibitors of tyrosine phosphatases for treating metabolic disorders, autoimmune diseases and neoplasm)

RN 874567-71-2 HCAPLUS

CN Benzoic acid, 2-(carboxymethoxy)-5-[[[(2-methoxyphenyl)sulfonyl][[4-(methylsulfonyl)phenyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 874568-56-6 HCAPLUS

CN Benzoic acid, 5-[[([1,1'-biphenyl]-2-ylmethyl)[(2-methoxyphenyl)sulfonyl]amino]methyl]-2-(carboxymethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1103761 HCAPLUS

DOCUMENT NUMBER: 143:387018

TITLE: Preparation of oxazole compounds containing phenoxyacetic acid moiety as PPAR α/γ agonists

INVENTOR(S): Kagechika, Hiroyuki; Shibata, Yoshihiro; Oguri, Atsushi

PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co. Ltd., Japan

Updated Search

10518778

SOURCE: PCT Int. Appl., 171 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005095364	A1	20051013	WO 2005-JP5740	20050328
WO 2005095364	C1	20060105		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2004-99201 A 20040330
JP 2005-15954 A 20050124

OTHER SOURCE(S): MARPAT 143:387018
GI



I



II

AB Title compds. I [Q = optionally substituted benzene, pyridine with OH, halo, alkenyl, etc.; R1 = optionally substituted Ph, pyridyl, pyrimidinyl, etc. with halo, alkenyl, alkoxy, etc.; R2 = optionally substituted pyridyl, pyrimidinyl, pyrazinyl, etc. with OH, halo, alkenyl, etc.; X, Y, Z = C, O, S, etc.; R3-R6 = H, alkyl, etc.; R7-R9 = H, alkyl; n = 0-3] were prepared For example, reductive amination of 2-formylthiazole with compound

Updated Search

II [R = H; OR' = tert-butoxy], e.g., prepared from 2-(3-bromophenyl)-4-chloromethyl-5-methylphenyloxazole in 4 steps, followed by treatment with HCl afforded compound II [R = thiazol-2-ylmethyl; OR' = OH] hydrochloride salt. In GAL4-hPPAR transactivation assays, compound II [R = thiazol-2-ylmethyl; OR' = OH] hydrochloride salt showed the EC50 value of 0.013 μM for PPARα. Of note, compds. I are useful as PPAR α/γ agonists for the treatment of diabetes.

IT 866639-69-2P 866639-72-7P 866639-76-1P
866639-78-3P 866639-80-7P 866639-82-9P
866639-84-1P 866639-86-3P 866639-88-5P
866639-92-1P 866639-94-3P 866639-96-5P
866639-98-7P 866640-00-8P 866640-02-0P
866640-04-2P 866640-06-4P 866640-10-0P
866640-12-2P 866640-14-4P 866640-16-6P
866640-18-8P 866640-20-2P 866640-22-4P
866640-24-6P 866640-26-8P 866640-28-0P
866640-30-4P 866640-32-6P 866640-34-8P
866640-36-0P 866640-38-2P 866640-42-8P
866640-44-0P 866640-46-2P 866640-48-4P
866640-50-8P 866640-53-1P 866640-59-7P
866640-62-2P 866640-64-4P 866640-66-6P
866640-68-8P 866640-69-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazole compds. containing phenoxyacetic acid moiety as PPAR α/γ agonists)

RN 866639-69-2 HCAPLUS

CN Propanoic acid, 2-methyl-2-[4-[[[2-(methylamino)-2-oxoethyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2-(2-propenyl)phenoxy]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 866639-68-1
CMF C28 H33 N3 O5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 866639-72-7 HCAPLUS
CN Propanoic acid, 2-[4-[[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl][2-(methylamino)-2-oxoethyl]amino]methyl]-2-(2-propenyl)phenoxy]-2-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 866639-71-6
CMF C28 H32 Br N3 O5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 866639-76-1 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl](2-oxazolylmethyl)amino]methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Updated Search



● HCl

RN 866639-78-3 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(methylamino)-2-oxoethyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 866639-80-7 HCAPLUS
CN Propanoic acid, 2-[4-[[[2-(dimethylamino)-2-oxoethyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 866639-82-9 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl](2-thiazolylmethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 866639-84-1 HCAPLUS
CN Propanoic acid, 2-[4-[[[(4,5-dihydro-5-oxo-1,3,4-oxadiazol-2-yl)methyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search



RN 866639-86-3 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-1,3,4-oxadiazol-2-yl)methyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 866639-88-5 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(3-methyl-1,2,4-oxadiazol-5-yl)methyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Updated Search



● HCl

RN 866639-92-1 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl](2-thiazolylmethyl)amino]methyl]phenoxy]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 866639-94-3 HCAPLUS
CN Propanoic acid, 2-[4-[[(2-benzoxazolylmethyl)[(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Updated Search



● HCl

RN 866639-96-5 HCAPLUS
CN Propanoic acid, 2-[4-[[bis[(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 866639-98-7 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(4-methyl-2-oxazolyl)methyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Updated Search



● HCl

RN 866640-00-8 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[(2-oxazolylmethyl)[(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]amino]methyl]phenoxy]-2-methyl-, hydrochloride (4:1) (9CI) (CA INDEX NAME)



●1/4 HCl

RN 866640-02-0 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[(2-oxazolylmethyl)[(5-phenyl-2-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, hydrochloride (4:3) (9CI) (CA INDEX NAME)

Updated Search



●3/4 HCl

RN 866640-04-2 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[(2-oxazolylmethyl)[[5-(2-thienyl)-1,3,4-oxadiazol-2-yl]methyl]amino]methyl]phenoxy]-2-methyl-, hydrochloride (2:1) (9CI) (CA INDEX NAME)



●1/2 HCl

RN 866640-06-4 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[(2-oxazolylmethyl)[[3-(2-thienyl)-1,2,4-oxadiazol-5-yl]methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search



RN 866640-10-0 HCAPLUS
CN Propanoic acid, 2-[2-methoxy-6-methyl-4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl](2-oxazolylmethyl)amino]methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 866640-12-2 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methyl][(5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search



RN 866640-14-4 HCAPLUS
CN Propanoic acid, 2-[4-[[[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methyl][(5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 866640-16-6 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl](2-thiazolylmethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search



RN 866640-18-8 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-phenyl-2-oxazolyl)methyl](2-thiazolylmethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 866640-20-2 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[[5-methyl-2-(5-methyl-2-thienyl)-4-oxazolyl]methyl](2-thiazolylmethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 866640-22-4 HCAPLUS

Updated Search

CN Propanoic acid, 2-[2,6-dimethyl-4-[[[[5-methyl-2-(5-methyl-2-thienyl)-4-oxazolyl]methyl](2-oxazolylmethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 866640-24-6 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[[5-methyl-2-(5-methyl-2-thienyl)-4-oxazolyl]methyl][(5-methyl-2-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 866640-26-8 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-2-oxazolyl)methyl][(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]amino]methyl]phenoxy]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Updated Search



●x HCl

RN 866640-28-0 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-2-oxazolyl)methyl][(5-phenyl-2-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 866640-30-4 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(methylamino)-2-oxoethyl][[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search



RN 866640-32-6 HCAPLUS
CN Propanoic acid, 2-[4-[[[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methyl][2-(methylamino)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 866640-34-8 HCAPLUS
CN Propanoic acid, 2-[4-[[[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]methyl][2-(methylamino)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 866640-36-0 HCAPLUS
CN Propanoic acid, 2-[2-methoxy-6-methyl-4-[[[2-(methylamino)-2-oxoethyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 866640-38-2 HCAPLUS

Updated Search

10518778

CN Propanoic acid, 2-[2-methoxy-6-methyl-4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl](2-thiazolylmethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 866640-42-8 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl](2-oxazolylmethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 866640-44-0 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[(2-oxazolylmethyl)[(5-phenyl-3-isoxazolyl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search



RN 866640-46-2 HCAPLUS
CN Propanoic acid, 2-[2-ethyl-4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl](2-oxazolylmethyl)amino]methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 866640-48-4 HCAPLUS
CN Propanoic acid, 2-[2-ethyl-6-methyl-4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl](2-oxazolylmethyl)amino]methyl]phenoxy]-2-methyl-, hydrochloride (20:17) (9CI) (CA INDEX NAME)

Updated Search



●17/20 HCl

RN 866640-50-8 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl][[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]methyl]amino]methyl]phenoxy]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 866640-53-1 HCAPLUS
CN Propanoic acid, 2-[4-[[[(4,5-dihydro-4-methyl-5-oxo-1,3,4-oxadiazol-2-yl)methyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search



RN 866640-59-7 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methyl][(3-methyl-1,2,4-oxadiazol-5-yl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 866640-62-2 HCAPLUS
CN Propanoic acid, 2-[4-[[[2-(cyclopropylamino)-2-oxoethyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search



RN 866640-64-4 HCAPLUS
CN Propanoic acid, 2-[4-[[[2-[(cyclopropylmethyl)amino]-2-oxoethyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 866640-66-6 HCAPLUS
CN Propanoic acid, 2-[4-[[[2-(butylamino)-2-oxoethyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 866640-68-8 HCAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl][[5-(3-pyridinyl)-1,3,4-oxadiazol-2-yl]methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search



RN 866640-69-9 HCAPLUS
CN Propanoic acid, 2-[4-[[(2-amino-2-oxoethyl)[(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:980891 HCAPLUS
DOCUMENT NUMBER: 143:379070
TITLE: Minor structural modifications convert a selective PPARα agonist into a potent, highly selective PPARδ agonist
AUTHOR(S): Weigand, Stefan; Bischoff, Hilmar; Dittrich-Wengenroth, Elke; Heckroth, Heike; Lang, Dieter; Vaupel, Andrea; Woltering, Michael
CORPORATE SOURCE: Pharma Research, BAYER Health Care AG, Wuppertal, D-42096, Germany
SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(20), 4619-4623
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:379070

Updated Search

10518778

GI



I

AB We report the solid-phase synthesis and pharmacol. evaluation of a new series of small-mol. agonists of the human peroxisome proliferator-activated receptor δ (PPARδ) based on a lead structure from our PPARα program. Compound I showed good pharmacokinetics.

IT 518336-75-9P 518336-88-4P 866820-82-8P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(solid-phase preparation of small-mol. PPARδ agonists and evaluation for possible use for metabolic disorder treatment)

RN 518336-75-9 HCAPLUS

CN Propanoic acid, 2-[4-[[(cyclopropylmethyl)[2-[(2,4-dichlorophenyl)amino]-2-oxoethyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 518336-88-4 HCAPLUS

CN Propanoic acid, 2-[4-[[(cyclohexylmethyl)[2-[(2,4-dichlorophenyl)amino]-2-oxoethyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search

10518778



RN 866820-82-8 HCAPLUS
CN Propanoic acid, 2-[4-[[[2-[(2,4-dichlorophenyl)amino]-2-oxoethyl]phenylamino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:921438 HCAPLUS
DOCUMENT NUMBER: 143:259498
TITLE: Discovery and structure-activity relationships of novel sulfonamides as potent PTP1B inhibitors
AUTHOR(S): Holmes, Christopher P.; Li, Xianfeng; Pan, Yijun; Xu, Caiding; Bhandari, Ashok; Moody, Claire M.; Miguel, Joy A.; Ferla, Steven W.; De Francisco, M. Nuria; Frederick, Brian T.; Zhou, Siqun; Macher, Natalie; Jang, Larry; Irvine, Jennifer D.; Grove, J. Russell
CORPORATE SOURCE: Affymax, Inc., Palo Alto, CA, 94304, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(19), 4336-4341
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:259498
AB A series of novel sulfonamides containing a single difluoromethylene-phosphonate group were discovered to be potent inhibitors of protein tyrosine phosphatase 1B. Structure-activity relationships around the scaffold were investigated, leading to the identification of compds. with IC50 or Ki values in the low nanomolar range. These sulfonamide-based inhibitors exhibit 100 and 30 times higher inhibitory activity than the corresponding tertiary amines and carboxamides, resp.
IT 863976-92-5P 863976-94-7P 863976-95-8P

Updated Search

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(discovery and structure-activity relationships of novel sulfonamides as potent PTP1B inhibitors)

RN 863976-92-5 HCAPLUS
CN Acetic acid, [4-[[[[4-(difluorophosphonomethyl)phenyl]methyl](phenylmethyl)amino]sulfonyl]-2-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 863976-94-7 HCAPLUS
CN Acetic acid, [4-[[[[4-(difluorophosphonomethyl)phenyl]methyl](phenylmethyl)amino]sulfonyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 863976-95-8 HCAPLUS
CN Acetic acid, [4-[[[[4-(difluorophosphonomethyl)phenyl]methyl](phenylmethyl)amino]sulfonyl]-2,6-dimethylphenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:638735 HCAPLUS
DOCUMENT NUMBER: 143:153383
TITLE: Preparation of triazole, oxadiazole and thiadiazole derivatives as PPAR modulators for the treatment of diabetes
INVENTOR(S): Mantlo, Nathan Bryan; Navarro, Antonio; Saeed, Ashraf; Gernert, Douglas Linn; Ma, Tianwei; Pfeifer, Lance Allen

Updated Search

10518778

PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 175 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005065683	A1	20050721	WO 2004-US39775		20041221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004311909	A1	20050721	AU 2004-311909		20041221
PRIORITY APPLN. INFO.:			US 2003-532320P	P	20031222
			US 2004-586563P	P	20040709
			EP 2004-380158	A	20040721
			EP 2004-380159	A	20040721
			WO 2004-US39775	W	20041221

OTHER SOURCE(S): MARPAT 143:153383
GI



I



II

AB The title compds. I [X = a single bond, O, S, SO2 and N; U = an aliphatic

Updated Search

linker; Y = O, C, S, NH and a single bond; W = N, O or S; E = CR3R4A or A (wherein A = carboxy, tetrazole, alkylnitrile, carboxamide, sulfonamide and acylsufonamide; R3 = H, alkyl, alkoxy; R4 = H, alkyl, alkoxy, etc.; or R3 and R4 are optionally combined to form cycloalkyl); V = (hetero)alkyl, a bond; R1 = H, alkyl, heteroaryl, etc.; R8 = H, alkyl, alkenyl, halo; R9 = H, alkyl, halo, etc.; R10, R11 = H, OH, CN, etc.; R32 = a bond, H, halo, alkyl, etc.] which are modulators of peroxisome proliferator activated receptors (PPARs) and are useful for the treatment of diabetes and other metabolic disorders, were prepared and formulated. E.g., a multi-step synthesis of II, starting from Me glycolate and benzyl bromide, was given. The binding and cotransfection efficacy values for compds. I which are especially useful for modulating a PPAR receptor, are ≤ 100 nM and ≥ 50%, resp.

IT 860261-57-0P 860261-58-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazole, oxadiazole and thiadiazole derivs. as PPAR modulators for the treatment of diabetes)

RN 860261-57-0 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[methyl[[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-5-yl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 860261-58-1 HCAPLUS
CN Propanoic acid, 2-[4-[[[[1-ethyl-3-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-5-yl]methyl]methylamino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:479502 HCAPLUS
DOCUMENT NUMBER: 143:172789

Updated Search

10518778

TITLE:	Design and Synthesis of α-Aryloxyphenylacetic Acid Derivatives: A Novel Class of PPARα/γ Dual Agonists with Potent Antihyperglycemic and Lipid Modulating Activity
AUTHOR(S):	Shi, Guo Q.; Dropinski, James F.; McKeever, Brian M.; Xu, Shihua; Becker, Joseph W.; Berger, Joel P.; MacNaul, Karen L.; Elbrecht, Alex; Zhou, Gaochao; Doebber, Thomas W.; Wang, Peiran; Chao, Yu-Sheng; Forrest, Mike; Heck, James V.; Moller, David E.; Jones, A. Brian
CORPORATE SOURCE:	Departments of Medicinal Chemistry, Metabolic Disorders, Atherosclerosis and Endocrinology and Animal Pharmacology, Merck Research Laboratories, Rahway, NJ, 07065-0900, USA
SOURCE:	Journal of Medicinal Chemistry (2005), 48(13), 4457-4468 CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER:	American Chemical Society
DOCUMENT TYPE:	Journal
LANGUAGE:	English
OTHER SOURCE(S):	CASREACT 143:172789

GI



I



II

AB The synthesis and structure-activity relationships of novel series of α-aryloxyphenylacetic acids as PPARα/γ dual agonists are reported. The initial search for surrogates of the ester group in the screen lead led first to the optimization of a subseries I (R1 = Et, Me2CH, Me3C, Ph; R2, R3 = H, Me, Cl, n-Pr, EtCHMe; R4 = H, F3C, Et, Me2CH, Me2CHO, Me2CHCH2) with a ketone moiety. Further efforts to modify the ketone subseries led to the design and synthesis of two new subseries containing fused heterocyclic ring systems, e.g. II (R5 = Me, Me2CH, cyclohexyl; R6 = H, Me2CH, Me2CHCH2) and oxazolone analogs. All these analogs were characterized by their "super" PPARα agonist activity and weak or partial agonist activity on PPARγ in PPAR-GAL4 transactivation assays despite their similar binding affinities for both receptors. The cocrystal structures of II (R5 = Me; R6 = Me2CH) and rosiglitazone with PPARγ-LBD were compared, and significant differences were found in their interactions with the receptor. Select

analogs in each subseries were further evaluated for in vivo efficacy. They all showed excellent anti-hyperglycemic efficacy in a db/db mouse model and hypolipidemic activity in hamster and dog models without provoking the typical PPARγ-associated side effects in the rat tolerability assay.

IT 860780-59-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of α-aryloxy-, α-benzoxazolidinyloxy- and α-benzisoxazolidinyloxy-substituted arylacetic acids as PPARα/γ dual agonists with potent antihyperglycemic and lipid modulating activity)

RN 860780-59-2 HCAPLUS
CN Benzeneacetic acid, α-[4-[(dimethylamino)carbonyl]-2,6-dipropylphenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:120912 HCAPLUS
DOCUMENT NUMBER: 142:218965
TITLE: Preparation of alkynyl aryl carboxamides as protein-tyrosine phosphatase (PTP) inhibitors
INVENTOR(S): Swinnen, Dominique; Gerber, Patrick; Gonzalez, Jerome; Bombrun, Agnes; Jorand-lebrun, Catherine
PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth. Antilles
SOURCE: PCT Int. Appl., 198 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012280	A1	20050210	WO 2004-EP51557	20040720

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,

SN, TD, TG

AU 2004261400	A1	20050210	AU 2004-261400	20040720
CA 2527861	AA	20050210	CA 2004-2527861	20040720
EP 1654247	A1	20060510	EP 2004-766274	20040720

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRIORITY APPLN. INFO.:	EP 2003-102235	A	20030721
	US 2003-517993P	P	20031106
	WO 2004-EP51557	W	20040720

OTHER SOURCE(S): MARPAT 142:218965

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = alkynyl, alkynylaryl, or alkynylheteroaryl; X = aryl, heteroaryl, cycloalkyl or heterocyclyl; X1 = (un)substituted aryl; n = 0 or 1; R1 and R2 independently = H or alkyl; R3 = alkyl, alkenyl, aryl, etc.; R4 and R5 = H, OH, F, alkyl, carboxy, etc.] and their pharmaceutically acceptable salt are prepared and disclosed as modulators of protein-tyrosine phosphatases (PTP). Thus, e.g., II was prepared via coupling of 4-bromobenzaldehyde with 1-decyne followed by reductive amination with 6-amino-2,2-dimethyl-4H-1,3-benzodioxin-4-one (preparation given), amidation with 3-cyclopentylpropanoyl chloride and deprotection. Tested compds. display an inhibition (IC50 values) with regard to PTP of preferably less than 20μM, more preferred less than 5μM. As PTP inhibitors, I should be useful for the treatment and/or prevention of an inflammatory disorder, obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance. insulin resistance, hyperlipidemia, hypertriglyceridemia- hypercholesterolemia, polycystic ovary syndrome (PCOS).

IT 843674-70-4P 843674-71-5P 843674-72-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of alkynyl aryl carboxamides as protein-tyrosine phosphatase (PTP) inhibitors)

RN 843674-70-4 HCAPLUS

CN Benzoic acid, 2-(carboxymethoxy)-5-[[[[4-(1-decynyl)phenyl]methyl][(2E)-1-oxo-3-phenyl-2-propenyl]amino]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



Updated Search

RN 843674-71-5 HCAPLUS
CN Benzoic acid, 2-(carboxymethoxy)-5-[[(3-cyclopentyl-1-oxopropyl)[[4-(1-decynyl)phenyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 843674-72-6 HCAPLUS
CN Benzoic acid, 5-[[acetyl[[4-(1-decynyl)phenyl]methyl]amino]methyl]-2-(carboxymethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:2833 HCAPLUS
DOCUMENT NUMBER: 140:77141
TITLE: Preparation of 2-[4-(heteroarylaminomethyl)phenoxy]-2-methylpropanoates for treating a hPPAR mediated diseases
INVENTOR(S): Dodic, Nerina; Dumaitre, Bernard Andre; Gellibert, Francoise Jeanne; Sierra, Michael Lawrence
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000785	A2	20031231	WO 2003-EP6417	20030618
WO 2004000785	A3	20041014		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,

PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003237955	A1	20040106	AU 2003-237955		20030618
EP 1513796	A2	20050316	EP 2003-735642		20030618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005529965	T2	20051006	JP 2004-514763		20030618
US 2005222424	A1	20051006	US 2004-518347		20041217
PRIORITY APPLN. INFO.:			GB 2002-14139	A	20020619
			WO 2003-EP6417	W	20030618

OTHER SOURCE(S): MARPAT 140:77141
GI



I



II

AB The title compds. [I; R1, R2 = H, alkyl; R3, R4 = H, alkyl, OMe, CF, allyl, halo; n = 0-1; at least of X, Z and Y = O, S, N; R6 = alkyl, CF3, OMe, OCF3, halo; y = 0-5; R7 = H, CF3, alkyl (optionally substituted by phenyl), alkenyl with the proviso that when Z = S, O, R7 = H; R10 = H, alkyl; R5 = H, alkyl, alkoxyalkyl, alkenyl, alkoxy, etc.], useful for treatment of a hPPAR disease or condition such as dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia and anorexia nervosa (no biol. data given), were prepared Thus, reacting Et 2-(4-bromomethyl-2,6-dimethylphenoxy)-2-methylpropionate with [4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]thiophen-3-ylmethylamine (prepns. given) in the presence of cesium carbonate in 3-methyl-2-butanone followed by hydrolysis afforded II. Pharmaceutical composition comprising the compound I.

IT 639783-81-6P

Updated Search

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2-[4-(heteroarylaminomethylphenoxy])-2-methylpropanoates for treating a hPPAR mediated diseases)

RN 639783-81-6 HCAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[methyl[[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



IT 639783-82-7P 639783-90-7P 639783-92-9P
639783-94-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-[4-(heteroarylaminomethylphenoxy])-2-methylpropanoates for treating a hPPAR mediated diseases)

RN 639783-82-7 HCAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]methyl]propylamino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 639783-90-7 HCAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]-2-

Updated Search

propenylamino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 639783-92-9 HCAPLUS
CN Propanoic acid, 2-[4-[[(3-methoxypropyl)[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639783-94-1 HCAPLUS
CN Propanoic acid, 2-[4-[[(2-furanylmethyl)[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search



L4 ANSWER 11 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:2818 HCAPLUS
DOCUMENT NUMBER: 140:59406
TITLE: Preparation of [[[(hetero)arylamino]methyl]phenoxy]acetic acid derivatives as hPPAR activators for treatment of cardiovascular disease and related disorders
INVENTOR(S): Beswick, Paul John; Harling, John David; Kleanthous, Savvas; Patel, Vipulkumar Kantibhai; Simpson, Juliet
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000762	A2	20031231	WO 2003-EP6416	20030618
WO 2004000762	A3	20041014		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2489359	AA	20031231	CA 2003-2489359	20030618
AU 2003245963	A1	20040106	AU 2003-245963	20030618
EP 1513795	A2	20050316	EP 2003-738057	20030618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011935	A	20050322	BR 2003-11935	20030618
CN 1675168	A	20050928	CN 2003-819322	20030618
JP 2005534673	T2	20051117	JP 2004-514762	20030618

Updated Search

10518778

NO 2004005327	A	20050310	NO 2004-5327		20041203
US 2006074111	A1	20060406	US 2004-518778		20041217
PRIORITY APPLN. INFO.:			GB 2002-14254	A	20020620
			WO 2003-EP6416	W	20030618

OTHER SOURCE(S): MARPAT 140:59406

GI



I



II

AB Title compds. I [wherein R1 and R2 = independently H or alkyl; X = a bond, CH2, or O; R3 and R4 = independently H, alkyl, OCH3, CF3, allyl, or halo; X1 = CH2, SO2, or CO; R5 = alkenyl, alkanoyl, alkylsulfonyl, or (un)substituted alkyl(phenyl); R6 = (un)substituted Ph or 6-membered heteroaryl; or pharmaceutically acceptable salts, solvates, or hydrolyzable esters thereof] were prepared as human peroxisome proliferator activated receptor (hPPAR) activators. For example, coupling of Et 2-methyl-2-[2-methyl-4-[[[4-(trifluoromethyl)benzyl]amino]methyl]phenoxy]p ropanoate with 2-bromo-6-[4-(trifluoromethyl)phenyl]pyridine in the presence of Pd(OAc)2, (R)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, and cesium carbonate in toluene gave the tertiary amine. Saponification with NaOH in THF provided the acid II. Compds. of the invention showed at least 50% activation of hPPARδ relative to the pos. control at concns. of 10-7 M or less. Thus, I and their pharmaceutical compns. are useful for the treatment of hPPAR mediated conditions, such as dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia, or anorexia nervosa (no data).

IT 637353-35-6P, [4-[[Butyl[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-36-7P, [4-[[(2-Methoxyethyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-37-8P, [2-Methyl-4-[[(pentyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]phenoxy]acetic acid 637353-38-9P, [4-[[(2-Cyclopropylethyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-39-0P, [2-Methyl-4-[[propyl[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]phenoxy]acetic acid 637353-40-3P,

Updated Search

[2-Methyl-4-[[[2-(methylthio)ethyl][4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]phenoxy]acetic acid 637353-41-4P, [4-[[Butyl[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-42-5P, [4-[[(2-Methoxyethyl)[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-43-6P, [4-[[(Butyryl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-44-7P, [2-Methyl-4-[[(propylsulfonyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]methyl]phenoxy]acetic acid 637353-45-8P, [4-[[Butyl[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]sulfonyl]-2-methylphenoxy]acetic acid 637353-46-9P, [2-Methyl-4-[[(pentyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]sulfonyl]phenoxy]acetic acid 637353-47-0P, [4-[[(2-Cyclopropylethyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]sulfonyl]-2-methylphenoxy]acetic acid 637353-56-1P, [4-[[Butyl(2,4'-dimethyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy]acetic acid 637353-57-2P, [4-[[Butyl(4'-fluoro-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy]acetic acid 637353-58-3P, [4-[[Butyl(4'-cyano-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy]acetic acid 637353-59-4P, [4-[[Butyl(4'-methoxy-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy]acetic acid 637353-60-7P, [4-[[Butyl(4'-chloro-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy]acetic acid 637353-61-8P, [4-[[(4'-Chloro-2-methyl-1,1'-biphenyl-3-yl)(2-methoxyethyl)amino]methyl]-2-methylphenoxy]acetic acid 637353-62-9P, [4-[[(2,4'-Dimethyl-1,1'-biphenyl-3-yl)(2-methoxyethyl)amino]methyl]-2-methylphenoxy]acetic acid 637353-63-0P, [4-[[(2-Methoxyethyl)(4'-methoxy-2-methyl-1,1'-biphenyl-3-yl)amino]methyl]-2-methylphenoxy]acetic acid 637353-64-1P, [2-Methyl-4-[[[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl](propyl)amino]methyl]phenoxy]acetic acid 637353-65-2P, [4-[[(4'-Chloro-2-methyl-1,1'-biphenyl-3-yl)(propyl)amino]methyl]-2-methylphenoxy]acetic acid 637353-66-3P, [4-[[(2,4'-Dimethyl-1,1'-biphenyl-3-yl)(propyl)amino]methyl]-2-methylphenoxy]acetic acid 637353-67-4P, [4-[[(4'-Fluoro-2-methyl-1,1'-biphenyl-3-yl)(propyl)amino]methyl]-2-methylphenoxy]acetic acid 637353-68-5P, [4-[[(4'-Cyano-2-methyl-1,1'-biphenyl-3-yl)(propyl)amino]methyl]-2-methylphenoxy]acetic acid 637353-69-6P, [4-[[(4'-Methoxy-2-methyl-1,1'-biphenyl-3-yl)(propyl)amino]methyl]-2-methylphenoxy]acetic acid 637353-84-5P, [4-[[Butyl[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino]sulfonyl]-2-methylphenoxy]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hPPAR activator; preparation of [[[(hetero)arylamino]methyl]phenoxy]acetic acid derivs. as hPPAR activators for treatment of cardiovascular disease and related disorders)

RN 637353-35-6 HCAPLUS
CN Acetic acid, [4-[[butyl[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-36-7 HCAPLUS
CN Acetic acid, [4-[[(2-methoxyethyl)[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)





RN 637353-37-8 HCAPLUS
CN Acetic acid, [2-methyl-4-[[pentyl[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-38-9 HCAPLUS
CN Acetic acid, [4-[[(2-cyclopropylethyl)[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 637353-39-0 HCAPLUS
CN Acetic acid, [2-methyl-4-[[propyl[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-40-3 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-(methylthio)ethyl][4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)





RN 637353-41-4 HCAPLUS
CN Acetic acid, [4-[[butyl[2-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 637353-42-5 HCAPLUS
CN Acetic acid, [4-[[(2-methoxyethyl)[2-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)





RN 637353-43-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(1-oxobutyl)[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-44-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(propylsulfonyl)[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-45-8 HCAPLUS

Updated Search

CN Acetic acid, [4-[[butyl[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]sulfonyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-46-9 HCAPLUS
CN Acetic acid, [2-methyl-4-[[pentyl[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]sulfonyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-47-0 HCAPLUS
CN Acetic acid, [4-[[(2-cyclopropylethyl)[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]sulfonyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-56-1 HCAPLUS
CN Acetic acid, [4-[[butyl(2,4'-dimethyl[1,1'-biphenyl]-3-yl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 637353-57-2 HCAPLUS
CN Acetic acid, [4-[[butyl(4'-fluoro-2-methyl[1,1'-biphenyl]-3-yl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-58-3 HCAPLUS
CN Acetic acid, [4-[[butyl(4'-cyano-2-methyl[1,1'-biphenyl]-3-yl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-59-4 HCAPLUS
CN Acetic acid, [4-[[butyl(4'-methoxy-2-methyl[1,1'-biphenyl]-3-yl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-60-7 HCAPLUS
CN Acetic acid, [4-[[butyl(4'-chloro-2-methyl[1,1'-biphenyl]-3-yl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 637353-61-8 HCAPLUS
CN Acetic acid, [4-[[(4'-chloro-2-methyl[1,1'-biphenyl]-3-yl)(2-methoxyethyl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-62-9 HCAPLUS
CN Acetic acid, [4-[[(2,4'-dimethyl[1,1'-biphenyl]-3-yl)(2-methoxyethyl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-63-0 HCAPLUS
CN Acetic acid, [4-[[(2-methoxyethyl)(4'-methoxy-2-methyl[1,1'-biphenyl]-3-yl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search





RN 637353-64-1 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]propylamino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-65-2 HCAPLUS
CN Acetic acid, [4-[[(4'-chloro-2-methyl[1,1'-biphenyl]-3-yl)propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-66-3 HCAPLUS
CN Acetic acid, [4-[[(2,4'-dimethyl[1,1'-biphenyl]-3-yl)propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-67-4 HCAPLUS

Updated Search

10518778

CN Acetic acid, [4-[[(4'-fluoro-2-methyl[1,1'-biphenyl]-3-yl)propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-68-5 HCAPLUS
CN Acetic acid, [4-[[(4'-cyano-2-methyl[1,1'-biphenyl]-3-yl)propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-69-6 HCAPLUS
CN Acetic acid, [4-[[(4'-methoxy-2-methyl[1,1'-biphenyl]-3-yl)propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-84-5 HCAPLUS
CN Acetic acid, [4-[[butyl[2-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]amino]sulfonyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:696736 HCAPLUS
DOCUMENT NUMBER: 139:230769

Updated Search

10518778

TITLE: Preparation of (arylalkyl)thiazoles and oxazoles as peroxisome proliferator activated receptor modulators for treating diabetes mellitus and atherosclerosis

INVENTOR(S): Conner, Scott Eugene; Mantlo, Nathan Bryan; Zhu, Guoxin

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 153 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072102	A1	20030904	WO 2003-US2680	20030213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003214932	A1	20030909	AU 2003-214932	20030213
EP 1480642	A1	20041201	EP 2003-710780	20030213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005528346	T2	20050922	JP 2003-570848	20030213
US 2006084663	A1	20060420	US 2004-505103	20040817
PRIORITY APPLN. INFO.:			US 2002-359807P P	20020225
			WO 2003-US2680 W	20030213

OTHER SOURCE(S): MARPAT 139:230769

GI

Updated Search



I



II

AB Title compds. I [wherein R3 = H or alkoxy; R4 = H or alkyl; R5 = alkyl, alkenyl, or (un)substituted aryl(oxy)alkyl or arylthioalkyl; R6 = CF3, OCF3, (hydroxy)alkyl, alkylcarbamoyl, carboxyalkoxy, or (un)substituted aryloxy, arylthio, pyridinyl, pyrimidinyl, pyrazinyl, or arylalkyl; R7 and R8 = independently H, CF3, or alkyl; R9 and R10 = independently H, alkyl, alkenyl, or alkoxy; T1 = C or N; Q = bond, O, O(CH2)q, or C; q = 1-2; W = O, S, SO2, NHSO2, etc.; X = CmH2m; m = 0-2; Y and Z = independently O, N, or S wherein at least 1 of Y and Z = O or S; A = CO2H, alkylnitrile, CONH2, or (CH2)nCO2R19; n = 0-3; R19 = H or (un)substituted alkyl or arylmethyl; and pharmaceutically acceptable salts thereof] were prepared as peroxisome proliferator activated receptor (PPAR) agonists (no data). For example, (4-mercapto-2-methylphenoxy)acetic acid Et ester was coupled with 5-chloromethyl-4-phenethyl-2-(4-trifluoromethylphenyl)thiazole in the presence of Cs2CO3 in MeCN to give the (phenylthiomethyl)thiazole (83.5%), which was saponified with LiOH in THF to provide II. I and their pharmaceutical compns. are useful for the prevention and or treatment of diabetes mellitus and atherosclerosis (no data).

IT 592519-34-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR agonist; preparation of PPAR agonists for treating diabetes mellitus and atherosclerosis)

RN 592519-34-1 HCAPLUS

CN Benzenepropanoic acid, 4-[[bis[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]methyl]-2-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 592519-33-0
CMF C35 H31 F6 N3 O2 S2

Updated Search

10518778



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:696734 HCAPLUS
DOCUMENT NUMBER: 139:230768
TITLE: Preparation of (arylalkyl)thiazoles and oxazoles as peroxisome proliferator activated receptor modulators for treating diabetes mellitus, syndrome X, and cardiovascular disease
INVENTOR(S): Conner, Scott Eugene; Knobelsdorf, James Allen; Mantlo, Nathan Bryan; Schkeryantz, Jeffrey Michael; Shen, Quanrong; Warshawsky, Alan M.; Zhu, Guoxin
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 223 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072100	A1	20030904	WO 2003-US2679	20030213

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,

Updated Search

UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003217274	A1	20030909	AU 2003-217274		20030213
EP 1480640	A1	20041201	EP 2003-713316		20030213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
US 2005107449	A1	20050519	US 2003-505089		20030213
JP 2005529077	T2	20050929	JP 2003-570846		20030213
PRIORITY APPLN. INFO.:			US 2002-359808P	P	20020225
			WO 2003-US2679	W	20030213

OTHER SOURCE(S): MARPAT 139:230768

GI



I



II

AB Title compds. I [wherein R3, R4, R30, and R40= independently H, alkyl, halo, or alkoxy; R5 = (un)substituted alkyl, alkenyl, aryl(oxy)alkyl, or arylthioalkyl; or when R5 = alkyl, R5 may be combined with W to form a heterocycloalkyl fused to the oxazole or thiazole ring; R6 = trihalomethyl, trihalomethoxy, (hydroxy)alkyl, alkylcarbamoyl, tetramethyldioxaborolanyl, halo, alkanoyl, carboxyalkoxy, (cyclo)alkoxy, tetrahydropyranyloxy, morpholinyl, or (un)substituted aryloxy, arylthio, heterocyclyloxy, pyridinyl, pyrimidinyl, pyrazinyl, or arylalkyl; R7 and R8 = independently H, CF3, or alkyl; R9 = (un)substituted (aryl)alkyl or alkenyl; R10 = H or alkyl; Q = a bond, O, or CH2; T1 = C or N; W = CH2, O, OCH2, S, SO2, or (un)substituted CONH, NH, or NHCH2; X = C, CH2C, or CCH2; Y and Z = independently O, N, or S wherein at least 1 of Y and Z = O or S; A = CO2H, alkylnitrile, CONH2, or (CH2)nCO2R19; n = 0-3; R19 = H or alkyl; and pharmaceutically acceptable salts thereof] were prepared as peroxisome proliferator activated receptor δ (PPARδ) modulators (no data). For example, (4-mercapto-2-methylphenoxy)acetic acid Et ester was

condensed with 1-[4-[2-(2-chloro-6-fluorophenyl)ethyl]-2-(4-trifluoromethylphenyl)thiazol-5-yl]ethanol in the presence of PBu3 and 1,1'-(azodicarbonyl)bipiperidine in toluene. Deesterification with LiOH in THF produced II. I and their pharmaceutical compns. are useful for the prevention and or treatment of diabetes mellitus, syndrome X, and cardiovascular disease (no data).

IT 591777-10-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR modulator; preparation of PPAR modulators for treating diabetes mellitus, syndrome X, and cardiovascular disease)

RN 591777-10-5 HCAPLUS

CN Benzenepropanoic acid, 2-methyl-4-[[methyl[2-[4-(1-methylethyl)-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]propyl]amino]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 591777-09-2
CMF C28 H33 F3 N2 O2 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



Updated Search

10518778

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:335066 HCAPLUS
DOCUMENT NUMBER: 138:353734
TITLE: Preparation of phenoxyacetic acids as modulators of δ-peroxisome proliferator-activated receptors (PPAR-δ) for the treatment of dyslipidemia and coronary cardiac diseases
INVENTOR(S): Bischoff, Hilmar; Dittrich-Wengenroth, Elke; Heckroth, Heike; Vaupel, Andrea; Woltering, Michael; Weigand, Stefan
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035603	A1	20030501	WO 2002-EP11275	20021009
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10151390	A1	20030508	DE 2001-10151390	20011018
CA 2463226	AA	20030501	CA 2002-2463226	20021009
EP 1438285	A1	20040721	EP 2002-777295	20021009
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005506379	T2	20050303	JP 2003-538119	20021009
US 2005154061	A1	20050714	US 2003-492761	20021009

PRIORITY APPLN. INFO.: DE 2001-10151390 A 20011018
WO 2002-EP11275 W 20021009

OTHER SOURCE(S): MARPAT 138:353734
GI

Updated Search



I



II



III

AB Title compds. I [A = CH2, CH2CH2; X = O, S, CH2; R1, R2, R3 = H, alkyl, cycloalkyl, etc.; R4 = H, alkyl; R5, R6 = H, oxo; R7 = H, alkyl; R8 = alky, (CH2)nE; E = (un)substituted cycloalkyl, e.g., alkyl, CF3, OH, etc.; n = 1-2; R9, R10 = H, alkyl, alkoxy, etc.; R11, R12 = H, alkyl; R13 = H, hydrolyzable group (sic)] and their pharmaceutically acceptable salts were prepared For example, coupling of cyclohexylamine II, e.g., prepared from 4-hydroxy-3-methylbenzaldehyde in 2-steps, and 2-bromo-N-(2,4-dichlorophenyl)acetamide, followed by ester hydrolysis afforded phenoxyacetic acid III. In dose response studies on PPARδ-GAL4 chimeric receptors, the EC50 values of 7-examples of I ranged from 1-100 nM. The invention discloses the preparation of novel substituted acetic acid derivs., e.g., fibrates, for their use as potent compds. of PPAR-δ activation. Compds. I are claimed as medicaments for the treatment of dyslipidemia and coronary cardiac diseases.

IT 518336-74-8P 518336-75-9P 518336-76-0P
518336-78-2P 518336-86-2P 518336-88-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenoxyacetic acids as modulators of PPAR delta for the treatment of dyslipidemia and coronary cardiac diseases)

RN 518336-74-8 HCAPLUS

CN Propanoic acid, 2-[4-[[(cyclopropylmethyl)[2-[(2,4-difluorophenyl)amino]-2-oxoethyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 518336-75-9 HCAPLUS
CN Propanoic acid, 2-[4-[[(cyclopropylmethyl)[2-[(2,4-dichlorophenyl)amino]-2-oxoethyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 518336-76-0 HCAPLUS
CN Propanoic acid, 2-[4-[[[2-[(2,4-difluorophenyl)amino]-2-oxoethyl]heptylamino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 518336-78-2 HCAPLUS
CN Propanoic acid, 2-[4-[[[2-[(2,4-dichlorophenyl)amino]-2-oxoethyl]pentylamino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Updated Search



RN 518336-86-2 HCAPLUS
CN Propanoic acid, 2-[4-[[(cyclohexylmethyl)[2-[(2,4-dichlorophenyl)amino]-2-oxoethyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 518336-88-4 HCAPLUS
CN Propanoic acid, 2-[4-[[(cyclohexylmethyl)[2-[(2,4-dichlorophenyl)amino]-2-oxoethyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1985:95418 HCAPLUS
DOCUMENT NUMBER: 102:95418
TITLE: 2-(Dimethylamino)ethyl [methyl(dimethylsulfamoyl)phenoxy]acetates
INVENTOR(S): Oniscu, Cornelia; Nitelea, Ion; Botez, Gheorghe;

Updated Search

10518778

	Stanescu, Cornelia
PATENT ASSIGNEE(S):	Institutul de Cercetari Chimico-Farmaceutice, Rom.
SOURCE:	Rom., 2 pp.
	CODEN: RUXXA3
DOCUMENT TYPE:	Patent
LANGUAGE:	Romanian
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RO 77264	B	19810817	RO 1978-94788	19780726
PRIORITY APPLN. INFO.:			RO 1978-94788 A	19780726
OTHER SOURCE(S):	CASREACT 102:95418			

GI



I

AB Esters I (R = H, Me), which were prepared, are useful as central nervous system stimulants (no data). Thus, 2,4-Me(Me2NSO2)C6H3OCH2CO2H was converted to its acid chloride, and the latter was treated with Me2NCH2CH2OH to give the appropriate I (R = H).

IT 29148-99-0 94882-99-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(esterification of, by ethanolamine derivative)

RN 29148-99-0 HCAPLUS

CN Acetic acid, [4-[(dimethylamino)sulfonyl]-2,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RN 94882-99-2 HCAPLUS

CN Acetic acid, [4-[(dimethylamino)sulfonyl]-2,6-dimethylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search

10518778



IT 29148-95-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with thionyl chloride)
RN 29148-95-6 HCAPLUS
CN Acetic acid, [4-[(dimethylamino)sulfonyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1984:530416 HCAPLUS
DOCUMENT NUMBER: 101:130416
TITLE: (Dimethylamino)ethyl esters of 2-(sulfamoylphenoxy)propionic acids
INVENTOR(S): Oniscu, Corneliu; Bibian Cilianu, Stefan; Dobrescu, Dumitru; Chirita, Mihai; Szekeli, Zoltan; Murgu, Lucia
PATENT ASSIGNEE(S): Institutul de Cercetari Chimico-Farmaceutice, Rom.
SOURCE: Rom., 3 pp.
CODEN: RUXXA3
DOCUMENT TYPE: Patent
LANGUAGE: Romanian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RO 82051	B	19830707	RO 1981-104368	19810522

PRIORITY APPLN. INFO.: RO 1981-104368 19810522
OTHER SOURCE(S): CASREACT 101:130416
GI

Updated Search

10518778



I

AB Esters I (R = H, Me; R1 = H, Cl, Me, OMe) were prepared, and they are useful as central nervous system stimulants (no data). Thus, 4,2-Cl(Me2NSO2)C6H3OCHMeCO2H was treated with SOCl2 and Me2NCH2CH2OH to give 4,2-Cl(Me2NSO2)C6H3OCHMeCO2CH2CH2NMe2.

IT 49816-52-6 91859-24-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(esterification of, by thionyl chloride and ethanolamine derivative)

RN 49816-52-6 HCAPLUS

CN Propanoic acid, 2-[4-[(dimethylamino)sulfonyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 91859-24-4 HCAPLUS

CN Propanoic acid, 2-[4-[(dimethylamino)sulfonyl]-3-methylphenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1983:483603 HCAPLUS
DOCUMENT NUMBER: 99:83603

Updated Search

10518778

TITLE: Laboratory screening tests of systemic and chemotherapeutic fungicidal activity of some aryloxyalkanecarboxylic acid derivatives

AUTHOR(S): Stec, Maria; Eckstein, Zygmunt
CORPORATE SOURCE: Inst. Org. Chem. Technol., Tech. Univ., Warsaw, Pol.

SOURCE: Acta Phytopathologica Academiae Scientiarum Hungaricae (1982), 17(1-2), 179-91
CODEN: APYPBZ; ISSN: 0001-6780
DOCUMENT TYPE: Journal
LANGUAGE: English

GI



II, R=H, R^1=CH=$CHNO_2$
III, R=CH=$CHNO_2$, R^1=H



IV

AB Of 66 compds. of the general formula ArOCH(R)COX (I; R = H or Me; X = HNOH, OMe, OEt, or OH; Ar = 1-naphthalenyl and substituted phenyls), those having the 2-nitrovinyl toxophor on the phenoxyacetic acid moiety, especially in positions 3 or 4, were the most effective against Phytophthora infestans on the 3 apical leaves of tomato. The sulfanamide and hydrazide toxophors on phenoxyacetic or (±)-2-phenoxypropionic acid derivs. also were highly effective. Mevin (II) [24602-89-9], Pavin (III) [24634-65-9], 2,4,6-TH (IV) [13370-24-6], and I; R = H, X = HNOH, Ar = C10H7-(1) [13370-51-9] also showed protective and systemic activity on potatoes. Most of 20 compds. effective against Alternaria tenuis and Venturia inaequalis in vitro, contained 1,3-dioxacyclane and 2-nitrovinyl groups.

IT 27455-81-8 49816-52-6
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)
(fungicidal activity of)

RN 27455-81-8 HCAPLUS
CN Propanoic acid, 2-[4-[(dimethylamino)sulfonyl]-2,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search

10518778



RN 49816-52-6 HCAPLUS
CN Propanoic acid, 2-[4-[(dimethylamino)sulfonyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1975:156014 HCAPLUS
DOCUMENT NUMBER: 82:156014
TITLE: Chromanones derived from β-cresoxypropionic acids
AUTHOR(S): Cocarla, I.; Mazilu, I.; Nicu, M.; Botez, Gh.
CORPORATE SOURCE: Inst. Politeh., Iasi, Rom.
SOURCE: Buletinul Institutului Politehnic din Iasi, Sectia 2: Chimie (1973), 19(1-2), 83-9
CODEN: BICMCF; ISSN: 0373-3246
DOCUMENT TYPE: Journal
LANGUAGE: Romanian
GI For diagram(s), see printed CA Issue.
AB Chromones I (R = Me, R1 = SO2NMe2, SO2NEt2) were prepared by chlorosulfonylating 2-MeC6H4OCH2CH2CO2Et, aminating 2,4-Me(ClSO2)C6H3OCH2CH2CO2Et, hydrolyzing 2,4-Me(R1)C6H3OCH2CO2Et, and cyclizing the acids with PCl5-AlCl3. I (R = SO2NMe2, SO2NEt2, R1 = Me) were similarly prepared from 4-MeC6H4OCH2CH2CO2Et.
IT 55654-57-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of)
RN 55654-57-4 HCAPLUS
CN Propanoic acid, 3-[4-[(diethylamino)sulfonyl]-2-methylphenoxy]- (9CI) (CA

Updated Search

INDEX NAME)



IT 55654-55-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
RN 55654-55-2 HCAPLUS
CN Propanoic acid, 3-[4-[(dimethylamino)sulfonyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:545506 HCAPLUS
DOCUMENT NUMBER: 79:145506
TITLE: Nuclear magnetic resonance spectra of derivatives of aryloxyalkyl carboxylic sulfonamides. II. NMR spectra of sulfonamides of α-phenoxypropionic and α-phenoxybutyric acids
AUTHOR(S): Oniscu, Corneliu; Botez, Gh.
CORPORATE SOURCE: Inst. Politeh., Iasi, Rom.
SOURCE: Buletinul Institutului Politehnic din Iasi (1972), 18(3-4), 119-23
CODEN: BUPIAE; ISSN: 0032-6100
DOCUMENT TYPE: Journal
LANGUAGE: Romanian
GI For diagram(s), see printed CA Issue.
AB The NMR spectra of 42 sulfonamides (I, R = Me, Et; R1 = OH, OEt, NHNH2; R2 = OH, NH2, NMe2, NEt2, morpholino; R3, R4 = H, Cl, Me, OMe, Me2CH) derived from α-phenoxypropionic and α-phenoxybutyric acids were recorded at 60 MHz in Me2SO-d6 and analyzed. The spectra supported the assigned structures. When R2 = NH2 the sulfonamidic protons gave a singlet due to rapid exchange.
IT 49816-52-6

Updated Search

RL: PRP (Properties)
(NMR of)
RN 49816-52-6 HCAPLUS
CN Propanoic acid, 2-[4-[(dimethylamino)sulfonyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:498944 HCAPLUS
DOCUMENT NUMBER: 79:98944
TITLE: Nuclear magnetic resonance spectra of aminosulfonylphenoxyacetates
AUTHOR(S): Botez, Gh.; Oniscu, Corneliu
CORPORATE SOURCE: Inst. Politeh., Iasi, Rom.
SOURCE: Buletinul Institutului Politehnic din Iasi (1972), 18(3-4), 107-12
CODEN: BUPIAE; ISSN: 0032-6100
DOCUMENT TYPE: Journal
LANGUAGE: Romanian
AB The NMR of 38 derivs. of aminosulfonylphenoxyacetic acids, amides, and hydrazides with various substituents on the amine and on the benzene ring are reported.
IT 49816-52-6
RL: PRP (Properties)
(NMR of)
RN 49816-52-6 HCAPLUS
CN Propanoic acid, 2-[4-[(dimethylamino)sulfonyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



Updated Search

10518778

L4 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1972:405106 HCAPLUS
DOCUMENT NUMBER: 77:5106
TITLE: Monoethanolaminosulfonyl-, diethanolaminosulfonyl- and morpholinosulfonyl-phenoxyacetic derivatives
AUTHOR(S): Oniscu, Corneliu; Gorea, Camelia; Merica, Ecaterina; Botez, Gh.
CORPORATE SOURCE: Inst. Politeh., Iasi, Rom.
SOURCE: Buletinul Institutului Politehnic din Iasi (1971), 14(3-4), 101-14
CODEN: BUPIAE; ISSN: 0032-6100
DOCUMENT TYPE: Journal
LANGUAGE: Romanian
AB Treatment of (methylphenoxy)acetic acids with EtOH and H2SO4 at 78° gave rate consts. which were a function of the position of the Me group (2 > 4 > 3). Reaction of Et (methylphenoxy)acetates or (methylphenoxy)acetic hydrazides with HSO3Cl gave the sulfochlorides. Reaction of the sulfochlorides with monoethanolamine, diethanolamine, or morpholine gave 23 sulfonamides.
IT 36685-71-9P 36685-82-2P 36691-82-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 36685-71-9 HCAPLUS
CN Acetic acid, [4-[[bis(2-hydroxyethyl)amino]sulfonyl]-3-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 36685-82-2 HCAPLUS
CN Acetic acid, [4-[[bis(2-hydroxyethyl)amino]sulfonyl]-2,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RN 36691-82-4 HCAPLUS
CN Acetic acid, [4-[[bis(2-hydroxyethyl)amino]sulfonyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search

10518778



L4 ANSWER 22 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1971:498288 HCAPLUS
DOCUMENT NUMBER: 75:98288
TITLE: Phenoxybutyric acid sulfamides. I. Sulfamide derivatives of the α-phenoxy-, α-cresoxy-, and α-xylenoxybutyric acids
AUTHOR(S): Botez, Gh.; Gorea, Camelia; Oniscu, Corneliu; Merica, Ecaterina
CORPORATE SOURCE: Dep. Org. Ind., Polytech. Inst., Iasi, Rom.
SOURCE: Buletinul Institutului Politehnic din Iasi (1970), 16(1-2), 161-72
CODEN: BUPIAE; ISSN: 0032-6100
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Sulfamide derivs. (58) of α-phenoxy-(I), α-cresoxy-, and α-(xylyloxy)-butyric acids were prepared to study their hypocholesterolemic effects. The Et ester of I reacted with excess ClSO3H to give p-(ClO2S)C6H4OCH(Et)CO2Et, which reacted with NH3 in Me2CO to give Et α-(4-sulfamoylphenoxy)butyrate (II), with Me2NH to yield the N,N-dimethyl analog and with morpholine to give the morpholino analog. All esters on alkaline hydrolysis gave the free acids. II with NH2NH2 gave α-(p-sulfamoylphenoxy)-butyric acid hydrazide. Chlorosulfonation of Et α-(2-methylphenoxy)butyrate began at 3-9°, and ended at 15° to yield the 4-sulfamoyl derivative, which was converted into III [R = H, Me, Et, or (NR2 =) morpholino; R1 = H, Et, NHNH2; R2 = Me; R3 = R1 = H]. Similarly prepared were the III (R2 = R4 = H, R3 = Me), III (R2 = R3 = Me, R4 = H), III (R2 = R4 = Me, R3 = H), IV (R2 = R3 = H), IV (R2 = H, R3 = Me), and IV (R2 = Me, R3 = H) analogs.
IT 33491-38-2P 33491-41-7P 33491-42-8P
33491-55-3P 33491-65-5P 33491-66-6P
33602-19-6P 33815-06-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33491-38-2 HCAPLUS
CN Butyric acid, 2-[[4-(dimethylsulfamoyl)-o-tolyl]oxy]- (8CI) (CA INDEX NAME)

Updated Search



RN 33491-41-7 HCAPLUS
CN Butyric acid, 2-[[4-(dimethylsulfamoyl)-m-tolyl]oxy]- (8CI) (CA INDEX NAME)



RN 33491-42-8 HCAPLUS
CN Butyric acid, 2-[[4-(diethylsulfamoyl)-m-tolyl]oxy]- (8CI) (CA INDEX NAME)



RN 33491-55-3 HCAPLUS
CN Butyric acid, 2-[[4-(diethylsulfamoyl)-2,3-xylyl]oxy]- (8CI) (CA INDEX NAME)

Updated Search



RN 33491-65-5 HCAPLUS
CN Butyric acid, 2-[[4-(dimethylsulfamoyl)-2,5-xylyl]oxy]- (8CI) (CA INDEX NAME)



RN 33491-66-6 HCAPLUS
CN Butyric acid, 2-[[4-(diethylsulfamoyl)-2,5-xylyl]oxy]- (8CI) (CA INDEX NAME)



RN 33602-19-6 HCAPLUS
CN Butyric acid, 2-[[4-(diethylsulfamoyl)-o-tolyl]oxy]- (8CI) (CA INDEX NAME)



Updated Search

RN 33815-06-4 HCAPLUS
CN Butyric acid, 2-[[4-(dimethylsulfamoyl)-2,3-xylyl]oxy]- (8CI) (CA INDEX NAME)



L4 ANSWER 23 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1971:141206 HCAPLUS
DOCUMENT NUMBER: 74:141206
TITLE: Phenoxypropionic acid sulfonamides. II. Sulfonamidated derivatives of α-cresoxypropionic α-xylyloxypropionic acids
AUTHOR(S): Botez, Gh.; Gorea, Camelia; Merica, Ecaterina; Oniscu, Corneliu
CORPORATE SOURCE: Inst. Politeh., Iasi, Rom.
SOURCE: Buletinul Institutului Politehnic din Iasi (1969), 15(1-2), 67-78
CODEN: BUPIAE; ISSN: 0032-6100
DOCUMENT TYPE: Journal
LANGUAGE: Romanian
AB Potential plant growth regulators (38) were synthesized by treating Et α-cresoxypropionate and Et α-xylyloxypropionate with HSO3Cl (1:7, 15-40°); the chlorosulfonate derivs. were treated with NH3 or NHEt2 to form the corresponding sulfonamides, which, by alkaline hydrolysis gave the title compds. The hydrazides of the α-cresoxy and α-xylyloxypropionic acids were also prepared.
IT 31640-01-4P 31649-53-3P 31776-67-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 31640-01-4 HCAPLUS
CN Propionic acid, 2-[[4-(diethylsulfamoyl)-m-tolyl]oxy]- (8CI) (CA INDEX NAME)

10518778



RN 31649-53-3 HCAPLUS
CN Propionic acid, 2-[[4-(diethylsulfamoyl)-3,5-xylyl]oxy]- (8CI) (CA INDEX NAME)



RN 31776-67-7 HCAPLUS
CN Propionic acid, 2-[[4-(diethylsulfamoyl)-2,5-xylyl]oxy]- (8CI) (CA INDEX NAME)



L4 ANSWER 24 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1970:520246 HCAPLUS
DOCUMENT NUMBER: 73:120246
TITLE: Preparation and properties of some derivatives of sulfamylphenoxyacetic acid
AUTHOR(S): Eckstein, Zygmunt; Rusek, Dorota; Cudnoch, Stanislawa; Arct, Jacek
CORPORATE SOURCE: Zakl. Technol. Srodkow Ochr. Roslin, Politech. Warszaw., Warsaw, Pol.
SOURCE: Przemysl Chemiczny (1970), 49(6), 341-5
CODEN: PRCHAB; ISSN: 0033-2496
DOCUMENT TYPE: Journal
LANGUAGE: Polish
GI For diagram(s), see printed CA Issue.
AB Esters of the title compds. (I, Y = sulfonyl, alkylsulfamoyl or alkylaminosulfamoyl) were prepared from I (R = alkyl, Y = H, X = H, halogen

Updated Search

or alkyl) by treatment with ClSO3H at 0-40° and then with NH3, amines or hydrazine. Thus I (R = Me, Y = SO2NHEt-4, X = H) (Ia) and 30 other I were prepared Ia was hydrolyzed with 5% NaOH to give I (R = X = H, Y = SO2NHEt-4) (II). Similarly prepared were 9 II analogs. I and II were screened for mycostatic action and elongation of plant cells.

IT 29148-95-6P 29148-99-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 29148-95-6 HCAPLUS
CN Acetic acid, [4-[(dimethylamino)sulfonyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 29148-99-0 HCAPLUS
CN Acetic acid, [4-[(dimethylamino)sulfonyl]-2,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 25 OF 26 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1970:434965 HCAPLUS
DOCUMENT NUMBER: 73:34965
TITLE: Preparation and properties of some derivatives of (+-)-2-(sulfamylaryloxy)-propionic acid
AUTHOR(S): Krassowska, Barbara; Ejmocki, Zdzislaw; Eckstein, Zygmunt
CORPORATE SOURCE: Politech. Warszawskiej, Warsaw, Pol.
SOURCE: Przemysl Chemiczny (1970), 49(4), 218-22
CODEN: PRCHAB; ISSN: 0033-2496
DOCUMENT TYPE: Journal
LANGUAGE: Polish

AB Preparation of derivs. of racemic 2-aryloxyalkanecarboxylic acids, substituted in o- or p-position with a sulfamoyl, N-alkyl, or N-methoxysulfamoyl group are described. The compds. in question are of the general formula: R1R2NSO2ArOCHMeCO2Me. The starting materials for their synthesis were several racemic 2-aryloxypropionic acids [ArOCHMeCO2H], obtained by condensation of 1-cyanoethyl benzenesulfonate [PhS(O)2OCH(CN)Me] with phenol, 2-methyl-, 2,5-dimethyl-4-chloro-3-methyl-, or 2,5-dichlorophenol,

Updated Search

and with 1-naphthol. All of the above 2-aryloxypropionic acids were esterified with MeOH (70-90% yields), the Me esters were dissolved in CHCl3 and treated with ClSO2OH, and the resulting crude sulfonyl chlorides were reacted (in Me2CO or C6H6 solution) with NH3, N-methyl-, N-methoxy-, or N,N-dimethylamine. The yields, m.ps., and the characteristic ir absorption bands of the various Me esters [ArOCHMeCO2Me] and free acids [ArOCHMeCO2H] prepared by the authors are tabulated. The substituents in the aromatic nucleus were chosen in order to maximize fungicidal activity and minimize plant growth regulatory effects. The compds. showed good systematic fungicidal activity against Phytophthora infestans and were effective in treating tomatoes infected with this pathogen.

IT 27455-81-8P 49816-52-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 27455-81-8 HCAPLUS
CN Propanoic acid, 2-[4-[(dimethylamino)sulfonyl]-2,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RN 49816-52-6 HCAPLUS
CN Propanoic acid, 2-[4-[(dimethylamino)sulfonyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



=> file caold
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION

Updated Search

10518778

FULL ESTIMATED COST 148.04 328.60

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION

CA SUBSCRIBER PRICE -19.50 -19.50

FILE 'CAOLD' ENTERED AT 14:07:18 ON 21 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 13:44:31 ON 21 AUG 2006)

FILE 'REGISTRY' ENTERED AT 13:45:23 ON 21 AUG 2006
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 197 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 14:03:46 ON 21 AUG 2006
L4 26 S L3
L5 1 S L4 AND BESWICK, P?/AU
L6 25 S L4 NOT L5
L7 0 S L6 AND HARLING, J?/AU
L8 0 S L6 AND KLEANTHOUS, S?/AU
L9 0 S L6 AND LAMBERT, M?/AU
L10 0 S L6 AND KANTIBHAI, V?/AU
L11 0 S L6 AND SIMPSON, J?/AU

FILE 'CAOLD' ENTERED AT 14:07:18 ON 21 AUG 2006

=> s l3
L12 1 L3

=> d l12, all, 1

L12 ANSWER 1 OF 1 CAOLD COPYRIGHT 2006 ACS on STN
AN CA60:6834d CAOLD
TI sulfonamides of phenoxyacetic acids - (III) imidazoline derivs. from sulfonamido compds. of phenoxyacetic acid and of cresoxyacetic acids and their hypotensive activity
AU Botez, Gh.; Enescu, L.

Updated Search

10518778

IT 25841-44-5 50283-86-8 90872-23-4 91013-73-9 91248-66-7 91248-67-8
92147-57-4 92491-64-0 93568-52-6 93568-53-7
93568-54-8 94025-11-3 94266-90-7 95295-63-9 96636-15-6

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.11	329.71

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-19.50

FILE 'REGISTRY' ENTERED AT 14:07:37 ON 21 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 AUG 2006 HIGHEST RN 902860-89-3
DICTIONARY FILE UPDATES: 20 AUG 2006 HIGHEST RN 902860-89-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> S 25841-44-5/RN

L13 1 25841-44-5/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L13 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 25841-44-5 REGISTRY
CN Benzenesulfonamide, 4-[(4,5-dihydro-1H-imidazol-2-yl)methoxy]-2-methyl-
(9CI) (CA INDEX NAME)

Updated Search

10518778

OTHER CA INDEX NAMES:
CN o-Toluenesulfonamide, 4-(2-imidazolin-2-ylmethoxy)- (7CI, 8CI)
OTHER NAMES:
CN 2-(4-Sulfamoyl-3-methyl-phenoxymethyl)-2-imidazoline
FS 3D CONCORD
MF C11 H15 N3 O3 S
CI COM
LC STN Files: CA, CAOLD, CAPLUS, TOXCENTER
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=>

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.34	332.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-19.50

FILE 'REGISTRY' ENTERED AT 14:08:00 ON 21 AUG 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 AUG 2006 HIGHEST RN 902860-89-3
DICTIONARY FILE UPDATES: 20 AUG 2006 HIGHEST RN 902860-89-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Updated Search

10518778

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> S 93568-53-7/RN

L14 1 93568-53-7/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L14 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L14 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 93568-53-7 REGISTRY
CN Acetic acid, [[4-(diethylsulfamoyl)-m-tolyl]oxy]- (7CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H19 N O5 S
LC STN Files: CA, CAOLD, CAPLUS
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> SET NOTICE LOGIN DISPLAY

Updated Search

10518778

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=>

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.34	334.39

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-19.50

FILE 'REGISTRY' ENTERED AT 14:08:21 ON 21 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 AUG 2006 HIGHEST RN 902860-89-3
DICTIONARY FILE UPDATES: 20 AUG 2006 HIGHEST RN 902860-89-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> S 93568-54-8/RN

L15 1 93568-54-8/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L15 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L15 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 93568-54-8 REGISTRY
CN Acetic acid, [[4-(diethylsulfamoyl)-o-tolyl]oxy]- (7CI) (CA INDEX NAME)

Updated Search

10518778

FS 3D CONCORD
MF C13 H19 N O5 S
LC STN Files: CA, CAOLD, CAPLUS
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=>

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.34	336.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-19.50

FILE 'REGISTRY' ENTERED AT 14:08:54 ON 21 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 AUG 2006 HIGHEST RN 902860-89-3
DICTIONARY FILE UPDATES: 20 AUG 2006 HIGHEST RN 902860-89-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Updated Search

10518778

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> S 50283-86-8/RN

L16 1 50283-86-8/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L16 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L16 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 50283-86-8 REGISTRY
CN Acetic acid, [4-[(diethylamino)sulfonyl]phenoxy]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Acetic acid, [p-(diethylsulfamoyl)phenoxy]- (6CI, 7CI)
FS 3D CONCORD
MF C12 H17 N O5 S
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CHEMCATS, TOXCENTER
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); PRP (Properties); NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> SET NOTICE LOGIN DISPLAY

Updated Search

10518778

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=>

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.34	339.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-19.50

FILE 'REGISTRY' ENTERED AT 14:09:12 ON 21 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 AUG 2006 HIGHEST RN 902860-89-3
DICTIONARY FILE UPDATES: 20 AUG 2006 HIGHEST RN 902860-89-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> S 91248-67-8/RN

L17 1 91248-67-8/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L17 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L17 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 91248-67-8 REGISTRY
CN Acetic acid, [(4-sulfamoyl-o-tolyl)oxy]-, ethyl ester (7CI) (CA INDEX
NAME)

Updated Search

10518778

FS 3D CONCORD
MF C11 H15 N O5 S
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=>

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.22	342.29

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-19.50

FILE 'REGISTRY' ENTERED AT 14:10:53 ON 21 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 AUG 2006 HIGHEST RN 902860-89-3
DICTIONARY FILE UPDATES: 20 AUG 2006 HIGHEST RN 902860-89-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Updated Search

10518778

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> S 94025-11-3/RN

L18 1 94025-11-3/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L18 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L18 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 94025-11-3 REGISTRY
CN Acetic acid, [p-(diethylsulfamoyl)phenoxy]-, ethyl ester (7CI) (CA INDEX NAME)
FS 3D CONCORD
MF C14 H21 N O5 S
LC STN Files: CA, CAOLD, CAPLUS
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

Updated Search

10518778

=>

Updated Search